In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are ...
Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...
Blood test predicts cardiac events and death in heart patients By Steve Tokar Mary Whooley, MD A simple blood test for the protein NT-proBNP accurately predicts the risk of heart attack, heart failure ...
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...
Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback